Genzyme Corporation

University of Florida Research Foundation Inc

Tracey Lodie

Michele Youd

Timothy D Connors

Ruiyin Chu

Jennifer Tedstone

Scott Eisenbeis

Karen B Carter

Jason Robert Pinckney

Elizabeth Masterjohn

Abraham Scaria

Donna Armentano

Mark A Atkinson

Ross A Tubo

The present disclosure provides anti-CXCR3 antibodies and methods of using the antibodies to diagnose and/or treat CXCR3-associated disorders such as diabetes mellitus type I (T1D), particularly new-onset T1D. In certain embodiments, disclosed herein are CXCR3 neutralizing antibodies.

Nucleic acids encoding anti-CXCR3 antibodies

Anti-CXCR3 antibodies and methods of use thereof

In accordance with the subject invention, combination therapies can be used to modulate a patient's immune response in order to prevent, delay and/or reverse type 1 diabetes.

Combination therapies for treating type 1 diabetes

Methods and compositions for treating an autoimmune disease, such as new onset type 1 diabetes (T1D) in a subject using autologous or allogeneic mesenchymal stem cells administered to the subject prior to autoimmune-induced complete depletion of insulin-producing pancreatic beta cells, e.g., within six months of new onset type 1 diabetes (T1D) diagnosis or prior to the onset of disease in a subject determined to be at high risk for T1D.

Method of treating autoimmune disease with mesenchymal stem cells

Growing community of inventors

Northbridge, MA, United States of America

Tracey Lodie